RNAi Technologies and Global Markets

Report Highlights

The global market for RNAi technology is estimated to increase from $2.1 billion in 2023 to reach $4.8 billion by 2029, at a compound annual growth rate (CAGR) of 14.8% from 2024 through 2029.

Report Includes

• 26 data tables and 53 additional tables
• An overview of the global market for RNAi technologies
• Analysis of global market trends, featuring revenue data for 2021- 2023, estimated figures for 2024, forecasts for 2029, and projected CAGRs through 2029
• Evaluation of the current market’s size and revenue growth prospects, along with a market share analysis by type, therapeutic area, delivery method, and region
• A look at innovations, technological advances, and recent product launches in the RNAi market
• Analysis of the industry’s regulatory framework and policies
• A discussion of ESG challenges and ESG practices in the RNAi technologies industry
• An analysis of the key companies’ market shares, proprietary technologies, and strategic alliances
• Company profiles of major players within the industry, including Alnylam Pharmaceuticals Inc., Novartis AG, Thermo Fisher Scientific Inc., and Revvity Inc.

Report Scope

The scope of this study encompasses an investigation of the ribonucleic acid interference (RNAi) technology market. BCC Research analyzes RNAi technology based on technology type: tools and reagents, diagnostics, therapeutics, and agriculture. BCC Research determines the current market status in each segment, examines its impact on future needs, and presents growth forecasts over the next six years. The report provides a detailed analysis of the market’s drivers, restraints, challenges, and opportunities. It includes company profiles of key players, with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides detailed information on emerging technologies and new developments in the market; examines the regulatory landscape; provides a patent and pipeline analysis; and discusses ESG developments, the investment outlook, and deals within the market.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.